PRECISE Phenotyping to Guide Therapies for Coronary Microvascular Dysfunction
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Empagliflozin 10mg OD.
- Who it may be relevant to
- Registry conditions: Coronary Microvascular Dysfunction (CMD). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Some people experience chest pain and shortness of breath, but when they have tests, no blockages are found in their main heart arteries. The most common cause of symptoms is related to abnormalities in the small blood vessels, also known as 'small vessel angina' or Coronary Microvascular Dysfunction (CMD). Currently, the diagnosis of CMD requires additional measurements of blood flow in the heart vessel during a minimally invasive procedure known as a coronary angiogram. CMD affects many people and can lead to repeated hospital visits and a lower quality of life, and diagnosing the condition leads to better patient outcomes. However, there are still no widely available, proven treatments for this condition and therefore several patients remain symptomatic. This study aims to find better ways to treat CMD, especially by understanding how the heart uses energy and how this might relate to symptoms.
Interventions
- Drug Empagliflozin 10mg OD
Drug
Primary outcome measures
- Myocardial Perfusion Reserve [Time frame: 8 weeks]
Eligibility criteria
Inclusion criteria
- Angina with non-obstructive coronary arteries
Exclusion criteria
- Significant epicardial coronary stenoses
- Inability to carry out bike exercise
- Contra-indication to adenosine administration
- Insulin usage with frequent hypoglycaemic episodes
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07533747 · 26/LO/0222